Benitec said this week that Michael Dalling has resigned as non-executive director of the board.
Dalling has been a Benitec director since March 2006, the company said.
Arrowhead Research said that Larry Stambaugh has stepped down as CEO of Arrowhead subsidiaries Insert Therapeutics and Calando Pharmaceuticals (see related story, this issue).
He will remain a consultant to Arrowhead, the company said.
Stambaugh’s departure comes amid a corporate restructuring that includes the merger of the two subsidiaries, which remains subject to Arrowhead shareholder approval.